4640-43-1

Basic information

• Product Name: 3-Aminocyclobutanone
• Synonyms: 3-Aminocyclobutanone;Cyclobutanone, 3-amino-
• CAS NO: 4640-43-1
• Molecular Formula: C₄H₇NO
• Molecular Weight: 85.10448
• Mol File: 4640-43-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Aminocyclobutanone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Aminocyclobutanone(4640-43-1)
• EPA Substance Registry System: 3-Aminocyclobutanone(4640-43-1)

Safety Data

• Hazardous Substances Data: 4640-43-1(Hazardous Substances Data)

Usage

Uses

Given the limited information available on 3-Aminocyclobutanone, its specific applications are not well-defined. However, based on its molecular structure and the properties of similar compounds, we can hypothesize potential uses in various industries:
Used in Pharmaceutical Industry:
3-Aminocyclobutanone could be used as a building block or intermediate in the synthesis of pharmaceutical compounds. Its amino and ketone functional groups may allow for the formation of various derivatives with potential therapeutic properties.
3-Aminocyclobutanone is used as a chemical intermediate for the synthesis of pharmaceutical compounds, leveraging its reactive functional groups to create novel therapeutic agents.
Used in Chemical Research:
3-Aminocyclobutanone may serve as a subject of study in chemical research, particularly in the fields of organic synthesis, medicinal chemistry, and materials science. Its unique structure and potential reactivity could provide insights into new chemical reactions and mechanisms.
3-Aminocyclobutanone is used as a research subject in chemical research to explore its properties, reactivity, and potential applications in various fields.
Used in Material Science:
The cyclobutane ring and functional groups present in 3-Aminocyclobutanone may endow it with specific material properties, such as stability, solubility, or reactivity. This could make it a candidate for the development of new materials with unique characteristics.
3-Aminocyclobutanone is used as a potential component in material science for the development of novel materials with unique properties based on its molecular structure.

Upstream product

• 130233-77-1 3-oxocyclobutane-1-carbonyl chloride 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 

Downstream Products

• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 
• 1449278-40-3 tert-butyl (7-(3-fluorophenyl)-4-((3-oxocyclobutyl)carbamoyl)isoquinolin-1-yl)carbamate 
• 1313759-93-1 N-(3-oxocyclobutyl)-2-naphthamide 

Relevant articles and documents

Preparation method of 3-oxocyclobutyl ammonia

The invention relates to a preparation method of 3-oxocyclobutyl ammonia. The preparation method of the 3-oxocyclobutyl ammonia comprises the following steps: conducting reaction on 3-oxocyclobutyl formamide serving as a starting material and an alkaline solution of hypohalous acid salt according to a certain proportion in a reaction solvent and 0 to 80 DEG C to prepare 3-oxocyclobutyl ammonia, diluting the system with water after the reaction, performing continuous extraction by using ethyl acetate, performing concentration under reduced pressure to obtain 3-oxocyclobutyl ammonia, and performing recrystallization on the product by diethyl ether to obtain a pure product. The preparation method of the 3-oxocyclobutyl ammonia is mild in reaction condition, high in speed, easy to operate and control and simple in aftertreatment, and the product has stable quality and high purity.

METHODS OF TREATING PULMONARY DISEASES AND DISORDERS

The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.

ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS

The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.

COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY

The present disclosure features compounds such as those having the Formulae (Ila), (lIb), (lIc), (Ild), (IlIa), and (Illb), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (Ila), (lIb), (lIc), (lId), (IlIa), or (Illb).

DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS

The present disclosure is based, in part, on the discovery that disclosed compounds can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.

COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY

The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.

COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY

The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.